Fat from two angles
AOD 9604 drives lipolysis to break down existing fat stores; MOTS-c activates AMPK to improve how your cells process fuel. One burns what's there, the other changes the trajectory — burning fat instead of storing it.
Back to all peptides
Unavailable
AOD 9604/MOTS-C
Fat Burning + Metabolic Reset
Energy
Dual-action combo for targeted fat burning and cellular metabolic optimization.
- Targeted fat reduction
- Improved insulin sensitivity
- Enhanced mitochondrial function
- Cellular metabolic reset
- No impact on blood sugar or IGF-1
Dosage3mg/mL (AOD 9604) + 5mg/mL (MOTS-C), 5mL vial
AdministrationSubcutaneous injection
Compounded in the U.S.A.
Temporarily unavailable from our compounding pharmacy. Check back soon.
About
What is AOD 9604/MOTS-C?
AOD 9604/MOTS-c puts two metabolic peptides in a single vial, attacking fat from two angles. AOD 9604 is the fat-burning fragment of growth hormone (amino acids 176–191) — it stimulates lipolysis and inhibits new fat storage, targeting adipose tissue directly, with no effect on blood sugar, IGF-1, or growth. MOTS-c is a mitochondrial-derived peptide that activates AMPK — the same metabolic switch exercise and fasting flip — improving insulin sensitivity, mitochondrial function, and metabolic flexibility.
Run together: AOD 9604 burns down existing fat stores while MOTS-c improves how your body processes fuel going forward — burning fat, not just storing it. It is a non-hormonal approach: no IGF-1 or cortisol changes, no stimulant jitters, no appetite suppression. The result is sustainable body-composition change layered on a genuine metabolic reset.
PeRx ships AOD 9604/MOTS-c fully reconstituted from an FDA-registered 503A pharmacy. No mixing — insulin syringes and a step-by-step guide arrive in the box. It is a subcutaneous injection on a provider-determined schedule.
Why do people explore AOD 9604/MOTS-C therapy?
Drives targeted fat reduction through lipolysis, the breakdown of stored fat, without affecting growth hormone or blood sugar.
Acts as an exercise mimetic at the cellular level. MOTS-c activates the same metabolic pathways that physical exercise triggers.
Improves insulin sensitivity and metabolic flexibility, so your body switches efficiently between burning fat and carbohydrates for fuel.
More mitochondria, more output. The combination enhances cellular energy production for better workouts and sustained daily energy.
Sustainable body composition changes without the hormonal side effects of full-length growth hormone therapy.
Why people explore AOD 9604/MOTS-C
A clearer path forward.
An exercise mimetic at the cellular level
MOTS-c activates the same AMPK pathway physical activity triggers — better insulin sensitivity, more mitochondria, more metabolic flexibility — so your workouts and nutrition actually produce the results they should.
AOD 9604 holds FDA GRAS status for its oral form; MOTS-c's AMPK activation is documented in Cell Metabolism.
Non-hormonal, no jitters
No effect on IGF-1, blood sugar, or cortisol; no stimulant crash; no appetite suppression. Fat metabolism happens through cellular signaling, not hormonal force.
What it helps with
Designed for these concerns.
- Targeted fat reduction
- Improved insulin sensitivity
- Enhanced mitochondrial function
- Cellular metabolic reset
- No impact on blood sugar or IGF-1
- Exercise-mimetic effects
- Supports sustainable body composition
Ideal for
Those wanting comprehensive metabolic optimization · Individuals with stubborn fat and metabolic sluggishness · Adults seeking non-hormonal fat loss support · Those interested in cellular energy improvement alongside fat loss
The science
How AOD 9604/MOTS-C works.
AOD 9604 stimulates lipolysis and inhibits fat storage without hormonal side effects. MOTS-C activates AMPK pathways to improve insulin sensitivity, mitochondrial function, and metabolic flexibility. Together they attack fat from two angles: burning existing stores and improving how your body uses energy.
01
Signal
AOD 9604/MOTS-c is given as a subcutaneous injection on a provider-determined schedule.
02
Cellular response
AOD 9604 stimulates lipolysis and inhibits fat storage without hormonal side effects. MOTS-c activates AMPK pathways to improve insulin sensitivity, mitochondrial function, and metabolic flexibility. Together they attack fat from two angles — burning existing stores and improving how your body uses energy.
03
Outcome
Over the following weeks most people notice steadier energy and fewer afternoon crashes first (weeks 1–2), then early fat loss around the midsection with workouts feeling more productive (weeks 2–4), then measurable body-fat reduction and better endurance and recovery (weeks 4–8), with metabolic markers like glucose and triglycerides often improving by week 8+. Diabetic patients should monitor blood glucose with their provider.
Subcutaneous injectionCompounded in the U.S.A. at a 503A pharmacyProvider-prescribed
What the research shows
Backed by published science.
176–191
The GH fat-burning fragment AOD 9604 isolates
AMPK
The exercise/fasting metabolic switch MOTS-c activates
GRAS
FDA Generally-Recognized-As-Safe status for AOD 9604 (oral form)
0
Effect on IGF-1, blood glucose, or cortisol
- AOD 9604 FDA GRAS status for oral form
- MOTS-C AMPK activation documented in studies
- Complementary fat-burning mechanisms
- Both well-tolerated independently
Lab tested medications
for quality & potency
Our medication is delivered from a state-licensed pharmacy in our network, right to your door when you need it.
Third-party quality control testing
Compounded in U.S. pharmacies
Lab tested for quality & potency
Our pharmacies perform third-party testing through FDA and DEA registered labs to run quality control checks for every compounded lot. They test four key characteristics associated with quality and safety.
Potency Test
PassedPerformed on every batch to confirm the active ingredient is present at the labeled concentration. Your vial contains exactly what it should.
Sterility Test
PassedTests for the presence of bacteria, fungi, and other microorganisms. Every batch is tested and must meet the requirements of USP 797.1.
Endotoxin Test
PassedScreens for bacterial endotoxins that can cause fever or adverse reactions. Every batch is tested and must not exceed the threshold limits defined in USP 85.
pH Test
PassedAssesses the acid/base balance to ensure minimal irritation upon injection and confirm the solution is within the correct range for subcutaneous administration.
What to expect
Your AOD 9604/MOTS-C timeline.
- 01
Week 1–2
Metabolic activation
What you may notice: Subtle energy improvements and reduced afternoon crashes. You may notice slightly less bloating and a feeling of metabolic "lightness" after meals.
What’s happening: AOD 9604 is beginning to stimulate lipolysis in fat stores. MOTS-c is activating AMPK pathways and improving how your mitochondria process fuel.
- 02
Week 2–4
Early fat loss
What you may notice: Clothes start fitting differently, especially around the midsection. Energy levels stabilize through the day. Exercise feels more productive.
What’s happening: Active fat breakdown is underway. MOTS-c is improving insulin sensitivity and metabolic flexibility — your body is getting better at switching between fuel sources.
- 03
Week 4–8
Visible results
What you may notice: Measurable reduction in body fat. Better workout endurance and recovery. Consistent energy without the mid-day crashes.
What’s happening: Sustained dual-action fat metabolism is reshaping body composition. Mitochondrial function is improving, which shows up as better energy and exercise capacity.
- 04
Week 8–12+
Metabolic optimization
What you may notice: Significant body-composition improvement. Metabolic markers like blood glucose and triglycerides often improve. Energy and exercise performance at their peak.
What’s happening: The full metabolic reset is established. Your body is burning fat more efficiently and producing cellular energy at a higher level.
Comparison
AOD 9604/MOTS-C vs. Tesamorelin/Ipamorelin
Two body-composition combos, different mechanisms — here's which fits.
| AOD 9604/MOTS-C | Tesamorelin/Ipamorelin | |
|---|---|---|
| Best for | Non-hormonal fat burning + a cellular metabolic reset | Visceral fat reduction + lean mass + sleep |
| How it works | Lipolysis (AOD 9604) + AMPK activation (MOTS-c) — no GH involved | GHRH + ghrelin pathways — GH-driven |
| Scope | Metabolic optimization and fat loss | Full body composition and recovery |
| Best if you have | Stubborn fat and metabolic sluggishness | Visceral fat, poor sleep, muscle loss |
| Can combine? | Yes — pairs well with CJC-1295/Ipamorelin | Yes — pairs well with MOTS-c, AOD 9604 |
FAQ
Common questions about AOD 9604/MOTS-C.
Patient reviews
What patients are saying.
No reviews yet. Be the first verified patient to share your experience.
This is not medical advice. Every patient's experience differs and not everyone qualifies for peptide therapy. All reviews are from verified PeRx patients and are published as submitted. Peptide therapy requires a valid prescription from a licensed provider.
Your safety, first
Important safety information.
- Generally well tolerated
- Possible injection site reactions
- Monitor blood glucose in diabetic patients
- Requires licensed provider supervision
All prescriptions are issued by a licensed US provider after reviewing your intake.
Side effects, contraindications, and what to discuss with your provider before starting.
Read safety informationSupporting research
Selected studies.
A selection of peer-reviewed work on AOD 9604/MOTS-C. Browse the full literature on PubMed and Google Scholar for ongoing research.
AOD 9604 fat reduction in obese subjects
Heffernan MA et al. Obes Res. 2004;12(8):1246–1254.MOTS-c regulates metabolic homeostasis
Lee C et al. Cell Metab. 2015;21(3):443–454.MOTS-c and exercise-induced physical decline
Reynolds JC et al. Nat Commun. 2021;12:470.
The statements on this page have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The FDA does not review or approve compounded medications for safety or effectiveness. Off-label use must be prescribed and supervised by a licensed provider.
You may also be interested in
Pairs well with.
Keep exploring
Learn more about AOD 9604/MOTS-C
Last updated April 2026
Medical disclaimer
The information provided on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Peptide therapy requires a valid prescription from a licensed healthcare provider. Individual results may vary. No specific outcomes are guaranteed.
The peptides on this site are not FDA-approved. They are compounded by licensed pharmacies under provider supervision. Certain peptides are prohibited by WADA and major sports organizations. Statements on this page have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Ready to start with AOD 9604/MOTS-C?
Take our 2-minute assessment. A licensed US provider reviews and, if appropriate, prescribes a protocol shipped to your door.